Literature DB >> 32445610

SCAI cardiogenic shock classification after out of hospital cardiac arrest and association with outcome.

Nilesh Pareek1,2, Rafal Dworakowski1,2, Ian Webb1,2, Jemma Barash1, Gift Emezu1, Narbeh Melikian1,2, Jonathan Hill1,2, Ajay Shah1,2, Philip MacCarthy1,2, Jonathan Byrne1,2.   

Abstract

OBJECTIVES: We aimed to validate the Society for Cardiovascular Angiography and Interventions (SCAI) classification to evaluate association with outcome in a real-world population and effect of invasive therapies.
BACKGROUND: Cardiogenic shock is common after Out of Hospital Cardiac Arrest (OOHCA) but is often multifactorial and challenging to stratify.
METHODS: The SCAI shock grade was applied to an observational registry of OOHCA patients on admission to our center between 2012 and 2017. The primary end-point was 30-day mortality and secondary end-points were mode of death and 12-month mortality. Provision of early CAG and mechanical circulatory support (MCS) was evaluated by SCAI shock grade using logistic regression.
RESULTS: Three hundred and ninety-three patients (median age 64.3 years (24.9% females) were included. One hundred and seven patients (27.2%) were in Grade A, 94 (23.9%) in Grade B, 66 (16.8%) in Grade C, 91 (23.2%) in Grade D, and 35 (8.9%) in Grade E. There was a step-wise significant increase in 30-day mortality with increasing shock grade (A 28.9% vs. B 33.0% vs. C 54.5% vs. D 59.3% vs. E 82.9%; p < .0001). With worsening shock grade, requirement for renal replacement therapy and mortality from multiorgan dysfunction syndrome and cardiogenic causes increased. Early CAG was performed equally in all groups but was significantly associated with reduced mortality in SCAI grade D only (OR 0.26 [CI 0.08-0.91], p = .036).
CONCLUSIONS: Increasing SCAI shock grade after OOHCA is associated with 30-day mortality, requirement for renal replacement therapy and mortality attributed to multiorgan dysfunction syndrome and cardiac etiology death.
© 2020 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.

Entities:  

Keywords:  SCAI classification; cardiac arrest; cardiogenic shock

Mesh:

Year:  2020        PMID: 32445610     DOI: 10.1002/ccd.28984

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

1.  Validation of the CREST score for predicting circulatory-aetiology death in out-of-hospital cardiac arrest without STEMI.

Authors:  Timothy N Jones; Matthew Kelham; Krishnaraj S Rathod; Charles J Knight; Alastair Proudfoot; Ajay K Jain; Andrew Wragg; Muhiddin Ozkor; Paul Rees; Oliver Guttmann; Andreas Baumbach; Anthony Mathur; Daniel A Jones
Journal:  Am J Cardiovasc Dis       Date:  2021-12-15

2.  Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.

Authors:  Rasha Kaddoura; Amr Elmoheen; Ehab Badawy; Mahmoud F Eltawagny; Mohamed A Seif; Khalid Bashir; Amar M Salam
Journal:  J Drug Assess       Date:  2021-07-20

Review 3.  The Stages of CS: Clinical and Translational Update.

Authors:  David A Baran; Ashleigh Long; Jacob C Jentzer
Journal:  Curr Heart Fail Rep       Date:  2020-11-14

4.  Application of the SCAI classification to admission of patients with cardiogenic shock: Analysis of a tertiary care center in a middle-income country.

Authors:  Héctor González-Pacheco; Rodrigo Gopar-Nieto; Diego Araiza-Garaygordobil; José Luis Briseño-Cruz; Guering Eid-Lidt; Jorge Arturo Ortega-Hernandez; Daniel Sierra-Lara; Alfredo Altamirano-Castillo; Salvador Mendoza-García; Daniel Manzur-Sandoval; Klayder Melissa Aguilar-Montaño; Heriberto Ontiveros-Mercado; Jorge Iván García-Espinosa; Pablo Esteban Pérez-Pinetta; Alexandra Arias-Mendoza
Journal:  PLoS One       Date:  2022-08-16       Impact factor: 3.752

5.  Prospective validation of the SCAI shock classification: Single center analysis.

Authors:  David A Baran; Ashleigh Long; Amit P Badiye; Kelly Stelling
Journal:  Catheter Cardiovasc Interv       Date:  2020-10-07       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.